Back to INCY
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Non-Small Cell Lung Cancer (NSCLC)
View Full LandscapeDrug Information
Patent & Exclusivity
ActiveRLD
Latest Patent Expiry
Oct 3, 2040(14 years)
Patents Listed
5
Exclusivity
ODE-292ODE-404
Application
NDA 213736Regulatory Approvals
EMA3/26/2021
Pemazyre
Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
OrphanConditional
View on EMADrug Science
Mechanism of action & safety profile
Developer
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts